drugset

drugset / Trial / NCT07553637

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

NCT07553637 ↗

Phase 2 Recruiting 178 enrolled Alto Neuroscience

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.

Timeline

Start: 2026-05
Primary completion: 2027-11
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALTO-207	Unknown	—	—

Indications